Clinical Trial

Study of JK06 in Patients With Unresectable Locally Advanced or Metastatic Cancer

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a Phase 1/2, open-label, multi-center, first-in-human, dose escalation and cohort expansion study evaluating multiple doses and schedules of intravenously administered JK06 in patients with unresectable locally, advanced or metastatic cancer.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-10-30; most recent amendment 2026-03-03.
Trial Details
NCT Number NCT06667960
Lead Sponsor Salubris Biotherapeutics Inc
Conditions Solid Tumor
Enrollment 255 participants
Start Date 2024-10-23
Primary Completion 2028-04-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-05